Results 11 to 20 of about 594,141 (367)

FDA no longer has to require animal testing for new drugs

open access: yesScience, 2023
Description Agency can rely on animal-free alternatives before human trials Agency can rely on animal-free alternatives before human ...
M. Wadman
semanticscholar   +1 more source

FDA: Fourier Domain Adaptation for Semantic Segmentation [PDF]

open access: yesComputer Vision and Pattern Recognition, 2020
We describe a simple method for unsupervised domain adaptation, whereby the discrepancy between the source and target distributions is reduced by swapping the low-frequency spectrum of one with the other. We illustrate the method in semantic segmentation,
Yanchao Yang, Stefano Soatto
semanticscholar   +1 more source

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics

open access: yesAAPS Journal, 2021
Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many cancer indications. This review provides an update on ICIs approved by the Food and Drug Administration (FDA), with focus on monoclonal antibodies that target the ...
J. Twomey, Baolin Zhang
semanticscholar   +1 more source

FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors

open access: yesClinical Cancer Research, 2021
The FDA approved pembrolizumab on June 16, 2020, for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden–high [TMB-H; ≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test ...
L. Marcus   +11 more
semanticscholar   +1 more source

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

open access: yesAntimicrobial Agents and Chemotherapy, 2020
Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of ...
Sangeun Jeon   +7 more
semanticscholar   +1 more source

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

open access: yesCancers, 2020
Cancer is associated with higher morbidity and mortality and is the second leading cause of death in the US. Further, in some nations, cancer has overtaken heart disease as the leading cause of mortality.
R. Vaddepally   +4 more
semanticscholar   +1 more source

Primary extranodal diffuse large B‐cell lymphoma: Molecular features, treatment, and prognosis

open access: yesAging and Cancer, Volume 3, Issue 3-4, Page 133-146, September-December 2022., 2022
One‐third of DLBCL arises from extranodal organs and is challenging to manage. Molecular features are critical to elucidate the differences in clinical features, predict the disease prognosis, and improve effective targeted therapeutic strategies. Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of non‐Hodgkin's lymphoma and ...
Si‐Yuan Chen   +3 more
wiley   +1 more source

Current FDA-Approved Therapies for High-Grade Malignant Gliomas

open access: yesBiomedicines, 2021
The standard of care (SOC) for high-grade gliomas (HGG) is maximally safe surgical resection, followed by concurrent radiation therapy (RT) and temozolomide (TMZ) for 6 weeks, then adjuvant TMZ for 6 months. Before this SOC was established, glioblastoma (
Jacob P. Fisher, D. C. Adamson
semanticscholar   +1 more source

DLI-IT: a deep learning approach to drug label identification through image and text embedding

open access: yesBMC Medical Informatics and Decision Making, 2020
Background Drug label, or packaging insert play a significant role in all the operations from production through drug distribution channels to the end consumer.
Xiangwen Liu   +5 more
doaj   +1 more source

Multiple sclerosis clinical decision support system based on projection to reference datasets

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1863-1873, December 2022., 2022
Abstract Objective Multiple sclerosis (MS) is a multifactorial disease with increasingly complicated management. Our objective is to use on‐demand computational power to address the challenges of dynamically managing MS. Methods A phase 3 clinical trial data (NCT00906399) were used to contextualize the medication efficacy of peg‐interferon beta‐1a vs ...
Chadia Ed‐driouch   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy